54
Participants
Start Date
July 28, 2017
Primary Completion Date
July 27, 2018
Study Completion Date
July 27, 2018
FLX-787-ODT (orally disintegrating tablet)
FLX-787-ODT taken three times daily for 28 days
Placebo ODT
Placebo ODT taken three times daily for 28 days
Hospital for Special Surgery, New York
University of Pittsburgh, Pittsburgh
Penn State Milton S. Hershey Medical Center, Hershey
Temple University, Philadelphia
GW Medical Faculty Associates Inc., Washington D.C.
Johns Hopkins Hospital, Baltimore
Virginia Commonwealth University, Richmond
Wake Forest University, Winston-Salem
Guilford Neurologic Associates, Greensboro
Medical University of South Carolina, Charleston
Emory University, Atlanta
Mayo Clinic, Jacksonville
University of South Florida Health, Tampa
Indiana University Neuroscience Center, Indianapolis
University of Iowa Hospitals and Clinics, Iowa City
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Saint Louis University, St Louis
University of Kansas Medical Center, Kansas City
UT Health San Antonio, San Antonio
Baylor Scott and White Health, Round Rock
Austin Neuromuscular Center, Austin
University of Colorado, Aurora
The University of Utah, Salt Lake City
Honor Health Research Institute, Scottsdale
Mayo Clinic, Scottsdale
California Pacific Medical Center, Sacramento
University of California San Francisco, San Francisco
University of California - Davis, Sacramento
Providence Brain and Spine Institute, Portland
Oregon Health Sciences University, Portland
Saint Luke's Rehabilitation Institute, Spokane
Hospital for Special Care, New Britain
Lahey Hospital and Medical Center, Burlington
University of Vermont Medical Center, Burlington
Lead Sponsor
Flex Pharma, Inc.
INDUSTRY